Collection from MedEngine

Caplacizumab prevents refractoriness and mortality in acquired thrombotic thrombocytopenic purpura: integrated analysis

Peyvandi et al. Blood Advances 2021; 5(8): 2137–2141.
This article was published on April 21, 2021, at ashpublications.org.
DOI: 10.1182/bloodadvances.2020001834

Select your desired language:

Supplementary material to accompany "Caplacizumab prevents refractoriness and mortality in acquired thrombotic thrombocytopenic purpura: integrated analysis"

Payvandi et al. Blood Advances; 2021, 5(8): 2137-2141
Access Supplementary Material
Content © 2021 by The American Society of Hematology
Site provided by Springer Healthcare. Part of the Springer Nature Group.
Privacy Policy